Matthew Kennedy
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)University of Waterloo(CA)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Cholinesterase and Neurodegenerative Diseases, Computational Drug Discovery Methods, Cinema and Media Studies, Parkinson's Disease Mechanisms and Treatments
Most-Cited Works
- → Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment(1991)575 cited
- → Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease(2020)434 cited
- → The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients(2016)410 cited
- → MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition(2015)329 cited
- → Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects(2014)310 cited
- → The roles of inflammation and immune mechanisms in Alzheimer's disease(2016)231 cited